On August 12, Sandoz announced that it had received FDA approval for its latest biosimilar: Enzeevu (aflibercept-abzu). This FDA approval includes the indication for wet age-related macular degeneration (or neovascular AMD [nAMD]). In Sandoz’s press release, Claire D’Abreu-Hayling, Chief Scientific Officer, Sandoz, said, “nAMD, or wet AMD, continues to be a leading cause of vision … Continue reading Enzeevu™ Joins Sandoz’s Ophthalmologic Biosimilar Franchise